Truist initiated coverage of Upstream Bio (UPB) with a Buy rating and $47 price target Verekitug offers similarly robust efficacy as other TSLP-receptor inhibitors, but with a much improved dosing schedule via targeting the receptor, the analyst tells investors. Given the size of the market and verekitug’s value proposition, the firm thinks it could “easily become a mega-blockbuster drug,” the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UPB:
- Upstream Bio management to meet with Piper Sandler
- Upstream Bio’s verekitug shows prevention of TSLP binding in respiratory disease
- Positive Phase 2 Results for Upstream Bio’s Verekitug Boost Stock Potential
- Positive Buy Rating for Upstream Bio, Inc. Driven by Promising Clinical Trial Results for Verekitug
- Upstream Bio Announces Positive Phase 2 Trial Results